BioLife Solutions Projects 17-20% Revenue Growth for 2026, Reports $96M FY2025 Revenue
BLFS sits 54% above its 52-week low of $17.86 on elevated volume (2.6× avg).
Summary
BioLife Solutions reported strong FY2025 results with $96 million in revenue and 29% organic growth, alongside a 26% adjusted EBITDA margin. The company also issued FY2026 guidance, projecting 17-20% revenue growth, positive GAAP net income, and continued adjusted EBITDA expansion. This investor presentation, detailed in an 8-K filed today, offers a clear financial outlook that is crucial for investor valuation and future expectations.
At the time of this announcement, BLFS was trading at $27.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $17.86 to $29.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.